CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
IMOJEVbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03920111
NCT03920111N/ACompleted
CompareCT.gov

Flavivirus Cross-priming Potential of Live Attenuated Japanese Encephalitis (JE) Vaccine IMOJEV in Flavivirus naïve and Flavivirus Experienced Participants

University of Liverpool·interventional·Posted Apr 18, 2019·Updated Jan 31, 2025

In Brief

A clinical study evaluating IMOJEV for Japanese Encephalitis. Completed, enrolled 19 participants across 1 site.

Detailed Summary

There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of next-generation vaccines. This study will use live chimeric JE vaccine IMOJEV® as a tool for flavivirus epitope discovery. This will allow experimental JEV infection using replication competent, live, attenuated virus as a model, in a setting where the flavivirus infection history of humans can be tightly controlled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 18, 2019
Enrollment StartApr 16, 2021
Primary CompletionDec 23, 2021
Study CompletionMay 11, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.2 years ago

Interventions

IMOJEVbiological

live attenuated Japanese encephalitis (JE) vaccine IMOJEV®